Transbronchial Versus Transthoracic Ablation for Early Stage Peripheral Lung Cancer: a Prospective, Randomized Controlled Trial
Sponsor study identifier
interventional
110
1 country
1
Study Start
October 11, 2023
Actual (reported)Primary Completion
April 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The purpose of this study is to investigate the efficacy and safety of RFA through a transthoracic or transbronchial approach in the treatment of early-stage peripheral lung cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 18, 2023
Actual (reported)September 25, 2023
Actual (reported)October 11, 2023
Actual (reported)April 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Complete ablation rate at 6 months after ablation
It is defined as the proportion of lesions with complete ablation to all ablated lesions at 6 months after ablation.
6 months
Technical success rate
Immediately after ablation
Complete ablation rate 12 months after ablation
12 months
Local control rate at 1 year, 2 years and 3 years after ablation
1 year, 2 years and 3years
Progression free survival (PFS)
3 years
Overall survival (OS)
3 years
Subjects receive bronchoscopy-guided RFA and undergo follow-up.
Subjects receive CT-guided RFA and undergo follow-up.
Procedure: In combination with guided bronchoscopy and CBCT, the ablation catheter is placed in the target lesion. CBCT confirms the tool in the lesion, adjusts the position of the ablation catheter, and monitors the extent of ablation.
Procedure: The ablation needle is punctured into the lesion under CT guidance. The extent of the ablation is monitored by CT.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
Jiayuan Sun, MD, PhD
Shanghai Chest Hospital
First Submitted
September 18, 2023
First Posted
September 25, 2023
Study Start
October 11, 2023
Actual (reported)Primary Completion
April 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Study Completion
October 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
December 6, 2023
Record last verified: 2023-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: